Cullinan Therapeutics
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing bispecific T cell engagers (CD19xCD3, BCMAxCD3, FLT3xCD3) and the partnered EGFR inhibitor zipalertinib for autoimmune diseases and oncology. Pre-commercial, with PDUFA set for February 2027.
- Company typePublic
- Founded2017
- HeadquartersCambridge, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Cullinan Therapeutics firmographics
Firmographics- Name
- Cullinan Therapeutics
- Legal name
- Cullinan Therapeutics, Inc.
- Website
- https://cullinanoncology.com
- Company type
- Public
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing bispecific T cell engagers (CD19xCD3, BCMAxCD3, FLT3xCD3) and the partnered EGFR inhibitor zipalertinib for autoimmune diseases and oncology. Pre-commercial, with PDUFA set for February 2027.
- Ownership category
- akta.pro rank
Cullinan Therapeutics industry classification
Industry- Product category
- Clinical-Stage Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
Keywords
Where Cullinan Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cullinan Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: As a clinical-stage biopharmaceutical company, Cullinan Therapeutics currently has no revenue. Future revenue will come from commercialization of approved drug products including zipalertinib (NSCLC), CLN-978 (autoimmune), velinotamig (autoimmune), and CLN-049 (AML). The company is not yet profitable and relies on equity financing and potential licensing/partnership deals.
- Licensing and Partnership Revenue: Partnership with Taiho Oncology/Taiho Pharmaceutical for zipalertinib development and commercialization. Taiho is responsible for completing the rolling NDA submission and will lead commercialization efforts in certain geographies, with Cullinan receiving potential milestone payments and royalties.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Cullinan Therapeutics product offering
Product offeringCore offering
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing T cell engager bispecific antibodies (CLN-978, velinotamig, CLN-049) and the EGFR inhibitor zipalertinib for autoimmune diseases and cancer. Its pipeline targets high-unmet-need indications including SLE, RA, lupus nephritis, EGFR exon 20 insertion NSCLC, and AML/MDS, with commercialization led through a partnership with Taiho Oncology for its lead oncology asset.
Product overview
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies in oncology and autoimmune diseases. The company's pipeline centers on T cell engager bispecific antibody programs: CLN-978 (CD19xCD3) and velinotamig (BCMAxCD3) target B cell-driven autoimmune diseases including SLE, RA, and lupus nephritis, while CLN-049 (FLT3xCD3) addresses acute myeloid leukemia. In oncology, zipalertinib (EGFR inhibitor, partnered with Taiho Oncology) is under FDA review for EGFR exon 20 insertion mutation NSCLC with PDUFA date February 27, 2027.
Differentiator
Problem solved
Functional benefit
Products and services
- CLN-978
- Velinotamig
- Zipalertinib
- CLN-049
Quantifiable outcome
- 35% confirmed objective response rate in 176 NSCLC patients with EGFR exon 20 insertions
- +5 more outcomes
Companies that use Cullinan Therapeutics
Customer profileSegments3 records
Ideal customer profiles1 record
Cullinan Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Cullinan Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Taiho Oncology / Taiho PharmaceuticalcoreCullinan Therapeutics partnered with Taiho Oncology and Taiho Pharmaceutical for the development and commercialization of zipalertinib, an oral EGFR tyrosine kinase inhibitor for EGFR exon 20 insertion mutation NSCLC. Taiho is responsible for completing the rolling NDA submission and will lead commercialization efforts in certain geographies, with Cullinan receiving potential milestone payments and royalties. The NDA is supported by Phase 2b REZILIENT1 trial data showing 35% confirmed ORR in 176 patients. PDUFA date is February 27, 2027.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Cullinan Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Amgen: Amgen is a global biopharmaceutical leader and pioneer of BiTE (bispecific T-cell engager) technology with Blincyto (CD19xCD3) approved in B-cell ALL. Directly comparable to Cullinan's TCE platform approach in both oncology and autoimmune applications, but at much larger scale.
- Roche: Roche markets multiple T-cell engaging bispecific antibodies including mosunetuzumab (CD20xCD3) and glofitamab (CD20xCD3), and has deep autoimmune commercial infrastructure. Comparable as a broad incumbent in the bispecific T-cell engager space with overlapping oncology and autoimmune ambitions.
- AbbVie: AbbVie co-developed epcoritamab (CD20xCD3, approved as Epkinly) with Genmab and has a significant autoimmune franchise. Relevant peer given bispecific TCE development and overlapping B-cell target approach for autoimmune indications like SLE and RA.
- Regeneron Pharmaceuticals: Regeneron is developing odronextamab (CD20xCD3) and has an established bispecific antibody platform through its Regeneron Bispecifics technology. Comparable as a TCE developer with strong oncology and autoimmune ambitions and significantly greater resources.
- Johnson & Johnson (Janssen): Janssen developed teclistamab (BCMAxCD3) and talquetamab (GPRC5DxCD3), and markets amivantamab (EGFRxMET) for EGFR exon 20 NSCLC directly competing with zipalertinib. Highly comparable across both Cullinan's TCE and EGFR exon 20 oncology programs.
- AstraZeneca: AstraZeneca acquired Gracell Biotechnologies and is developing T-cell engager and cell therapy programs in autoimmune and oncology. Direct peer in TCE platform development with overlapping autoimmune ambitions and significantly greater resources.
Direct peers
- MacroGenics: MacroGenics is a clinical-stage biotech developing multiple DART-format bispecific T-cell engagers including flotetuzumab (CD123xCD3) and enoblituzumab. Directly comparable as a clinical-stage peer focused on bispecific antibody platforms for oncology.
Emerging players
- Cabaletta Bio: Cabaletta Bio is developing CD19 CAR-T cell therapies for autoimmune diseases including SLE and lupus nephritis. Comparable as a peer pursuing deep B-cell depletion in autoimmune indications, though using cell therapy rather than bispecific TCE approach.
- Kyverna Therapeutics: Kyverna Therapeutics is developing CD19 CAR-T therapies for autoimmune diseases including SLE, myositis, and MS. Emerging peer in the autoimmune B-cell depletion space with similar patient populations to Cullinan's CLN-978 and velinotamig programs.
- Cartesian Therapeutics: Cartesian Therapeutics is developing engineered cell therapies and RNA-based immunotherapies for autoimmune diseases and oncology. Adjacent peer pursuing innovative immune-modulating approaches for autoimmune indications overlapping with Cullinan's TCE strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Cullinan Therapeutics social profiles
Digital presenceCullinan Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cullinan Therapeutics leadership team
Management profileNumber of profiles
Profiles11 records
Cullinan Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors24 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cullinan Therapeutics M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cullinan Therapeutics
What does Cullinan Therapeutics do?
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing T cell engager bispecific antibodies (CLN-978, velinotamig, CLN-049) and the EGFR inhibitor zipalertinib for autoimmune diseases and cancer. Its pipeline targets high-unmet-need indications including SLE, RA, lupus nephritis, EGFR exon 20 insertion NSCLC, and AML/MDS, with commercialization led through a partnership with Taiho Oncology for its lead oncology asset.
Is Cullinan Therapeutics a public or private company?
Cullinan Therapeutics is a public company. It is classified as public and is currently operating.
When was Cullinan Therapeutics founded?
Cullinan Therapeutics was founded in 2017. It employs 101 to 250 people.
Where is Cullinan Therapeutics based?
Cullinan Therapeutics is headquartered in Cambridge, United States, in the North America region.
How does Cullinan Therapeutics make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Partnership Revenue.
Who are Cullinan Therapeutics's main competitors?
Broad incumbents on record are Amgen, Roche, AbbVie, Regeneron Pharmaceuticals, Johnson & Johnson (Janssen) and AstraZeneca. MacroGenics is listed as a direct peer. Emerging players are Cabaletta Bio, Kyverna Therapeutics and Cartesian Therapeutics.
Does Cullinan Therapeutics have an API?
No public API is recorded for Cullinan Therapeutics.
What industry is Cullinan Therapeutics in?
Cullinan Therapeutics's product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2834.